SFPM(SZ:002737) Xin Lang Cai Jing·2025-11-18 09:54Core Points - The company, Kew Flower Pharmaceutical Group Co., Ltd., announced a board resolution on November 18, 2025, to allocate up to 50 million yuan for product research and development, focusing on traditional Chinese medicine, generic drug consistency evaluation projects, and expanding indications for existing products [1][2] - The board meeting was conducted via telecommunication, with all 9 participating directors voting in favor of the proposal, indicating unanimous support for the R&D initiatives [1] - The R&D investment aims to optimize the product structure and enhance the company's core competitiveness, reinforcing its long-term development strategy in the pharmaceutical sector [2] Summary by Categories R&D Investment - The company plans to invest no more than 50 million yuan in R&D, targeting three main areas: traditional Chinese medicine, generic drug consistency evaluation, and expanding indications for existing products [1] - This investment is intended to enrich the product pipeline and strengthen the company's long-term growth potential [1][2] Board Meeting Details - The fifth board's thirteenth meeting was held on November 18, 2025, with all 9 directors participating and voting unanimously in favor of the R&D proposal [1] - The decision falls within the board's authority and does not require shareholder approval, allowing management to control the project’s progress [1] Strategic Focus - Kew Flower Pharmaceutical continues to focus on its core pharmaceutical business, with this R&D funding expected to enhance its position in the innovation of traditional Chinese medicine and the quality improvement of generic drugs [2]